Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6577692 | 0.81 | OPRM1 (0.45) | MAPTRAB9AOPRM1OPRD1NPC1 | |
| SCHEMBL6573451 | 0.80 | OPRM1 (0.40) | MAPTOPRM1OPRD1LMNAKDM4E | |
| SCHEMBL6576189 | 0.79 | HTR1A (0.62) | OPRM1OPRD1HTR1A | |
| SCHEMBL6578109 | 0.74 | OPRM1 (0.40) | OPRM1OPRD1 | |
| SCHEMBL6575266 | 0.73 | SLC6A4 (0.48) | OPRM1OPRD1 | |
| SCHEMBL6577183 | 0.73 | OPRM1 (0.48) | OPRM1OPRD1 | |
| SCHEMBL8106540 | 0.69 | SLC6A4 (0.54) | KDM4E | |
| SCHEMBL10654773 | 0.67 | RAB9A (0.56) | MAPTRAB9ALMNASMN1; SMN2KDM4E | |
| SCHEMBL1101274 | 0.66 | MAPT (1.00) | MAPTRAB9ALMNASMN1; SMN2KDM4E | |
| SCHEMBL1101107 | 0.66 | RAB9A (0.55) | MAPTRAB9ALMNASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390364-B1 | ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | WYETH CORP (US) | 2004-09-29 | — | — | EP | claimed |
| EP-1390364-A1 | ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | Wyeth (US) | 2004-02-25 | — | — | EP | claimed |
| US-6632824-B2 | Have the ability to act at the 5-HT transporter. | WYETH | 2003-10-14 | — | — | US | claimed |
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | WYETH | 2003-02-13 | — | — | US | claimed |
| WO-2002096906-A1 | ARYL-8-AZABICYCLO[3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | WYETH (US) | 2002-12-05 | — | — | WO | claimed |
| EP-1390364-B1 | ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | WYETH CORP (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1390364-A1 | ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | Wyeth (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6632824-B2 | Have the ability to act at the 5-HT transporter. | WYETH | 2003-10-14 | — | — | US | disclosed |
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | WYETH | 2003-02-13 | — | — | US | disclosed |
| WO-2002096906-A1 | ARYL-8-AZABICYCLO[3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | WYETH (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | HTR1A, HTR1D, HTR2C | MAPT 2519/4885RAB9A 3217/4885OPRM1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.